Skip to main content

Table 1 Characteristics of patients with and without positive 18F-choline PET/CT

From: Predictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?

  Total PET-positive PET-negative p value
N 54 40 14  
Age at diagnosis (year) 62 (51–78) 61.5 (51–77) 62 (51–78) 0.57
Cancer characteristics     
Initial PSA (ng/mL) 9.84 (4–180) 9.58 (4–180) 10.51 (4.26–180) 0.86
Initial Gleason score 7 (5–9) 7 (5–9) 7 (6–9) 0.40
Gleason score ≥7 36 (67)    
TNM     0.79
 T11 11 (20.5) 8 (20) 4 (29)  
 T2 18 (33) 13 (32.5) 5 (35.5)  
 T3 24 (44.5) 19 (47.5) 5 (35.5)  
Other T (is, x) 1 (2)    
 N0 34 (63) 24 (60) 10 (71)  
 N1 2 (4) 2 (5) 0  
 N2 1 (2) 1 (2.5) 0  
 Nx 17 (31) 13 (32.5) 4 (29)  
D’Amico risk group     0.004
 High 38 (70.5) 31 (77.5) 7 (50)  
 Intermediate 11 (20.5) 4 (10) 7 (50)  
 Low 5 (9) 5 (12.5) 0  
Initial treatment     0.12
 RP 23 (43) 16 (40) 7 (50)  
 EBRT 28 (52) 23 (57.5) 5 (36)  
 Othera 3 (5) 1 (2.5) 2 (14)  
PSA values     
 PSA nadir (ng/mL) 0.31 (0.01–13.31) 0.30 (0.01–11.26) 0.50 (0.01–13.31) 0.40
 Pre-PET/CT PSA (trigger PSA) 7.85 (0.47–111.60) 9.14 (2.04–111.60) 4.25 (0.47–83.40) 0.015
 Relative PSA 6.05 (0.24–104.59) 8.06 (1.85–104.59) 2.34 (0.24–82.97) 0.0005
PSA kinetics     
 PSAdt in the last 12 m before PET/CT (months) 5.4 (0.6–91.6) 4.7 (1.7–27.7) 7.7 (0.6–91.6) 0.15
 PSA velocity (ng/mL/year) 6.40 (0.50–104.40) 8.10 (0.60–104.40) 3.05 (0.50–86.10) 0.01
PET/CT     
 ADT at time of PET/CT 12 (22) 11 (27.5) 1 (7) 0.11
 Time from initial treatment to PET/CT (months) 83 (4–222) 86 (4–222) 77 (11–123) 0.27
  1. All medians are followed by (min–max) interval
  2. ADT androgen deprivation therapy, EBRT external beam radiation therapy, PSA prostate-specific antigen, PSAdt PSA doubling time, RP radical prostatectomy
  3. aOther: hormonal therapy (n = 1), high-intensity focused ultrasounds (n = 1), transurethral resection of the prostate (n = 1)